Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News
July 19th 2024

In Value-Based Cancer Care, “Personalization Is Thriving, Standardization Is Trying to Keep Up”

July 12th 2024

“Personalized” Immunotherapy Appears Effective in Small Study of Patients With Metastatic Solid Tumors

July 3rd 2024

Study Finds Link Between Vitamin D Levels at Start of Immunotherapy and Overall Survival

June 17th 2024

FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma

June 16th 2024

Durvalumab Plus Chemotherapy Receives Approval for dMMR Primary Advanced or Recurrent Endometrial Cancer

ASCO 2024: Advances in Non-Small Cell Lung Cancer

A panel of experts discuss the value of biomarker testing for non-small cell lung cancer without driver mutations and strategies to optimize the outcomes of targeted therapies.

A panel of experts discuss the value of biomarker testing for non-small cell lung cancer without driver mutations and strategies to optimize the outcomes of targeted therapies.
Video Interviews
View All
December 1st 2023

Dr Guru Sonpavde on the Potential of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

September 25th 2023

Dr Erin Gillaspie Explains the Role of Immunotherapies in Lung Cancer Treatment

September 5th 2023

Dr Sigrun Hallmeyer: Precision Medicine Needs to Become More Efficient

September 1st 2023

Dr Jennifer Choe Discusses Head and Neck Cancer Relapse, New Treatment Trials, Promising Responses

July 22nd 2023

Dr Joseph Mikhael on Strategies to Increase CAR T-Cell Therapy Access

June 9th 2023

Disparities in Germline Genetic Testing Rates Exist, but Mechanisms Remain Unclear

May 21st 2023

Dr Mark Socinski on the Importance of Targeted Therapy and Immunotherapy in NSCLC

May 17th 2023

Dr Sigrun Hallmeyer Discusses Why a Team Effort Is Vital in Precision Medicine

May 8th 2023

Dr Kevin Davies Discusses Progress Made With CRISPR

April 18th 2023

Shiela Plasencia on the Use of Social Determinants Data Collection in Oncology Care

Podcasts
View All
August 11th 2018

Podcast: This Week in Managed Care—Step Therapy in Medicare Advantage and Other Health News

June 5th 2018

Addressing Financial Toxicity With Navigators and Better Conversations Around Decision Making

June 2nd 2018

Podcast: This Week in Managed Care—Bringing Down Health Insurance Premiums and Other Health News

More News

representation of targeted treatment | Image Credit: Kiattisak-stock.adobe.com
June 23rd 2024

Preclinical Study Shows Promise of Dual Targeted Treatment Against TNBC

AJMC Contributor
Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.
Blinatumomab logo | Image credit: Amgen
Published: June 14th 2024 | Updated: June 14th 2024

Blinatumomab Approved in Consolidation Phase for CD-19+ Ph-Negative Precursor B-ALL, “Redefines Standard of Care”

AJMC Staff
Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said.
Esophageal cancer illustration | Image credit: Dr_Microbe - stockadobe.com
June 14th 2024

Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

Laura Joszt, MA
The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.
CAR T-cell therapy | Image credit: Getty Images Science Library
June 12th 2024

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

Sang Chau, PharmD, BCOP Justin Tse, PharmD, BCOP Amy VanGalder, PharmD, BCOP Garrick Wong, PharmD Terra Wonsettler, PharmD, MBA Andrew Hertler, MD, FACP
Older male patient speaking with doctor | Image credit: DragonImages - adobe.stock.com
June 7th 2024

Dr Christopher Flowers: Liso-Cel Approval for Mantle Cell Lymphoma Changes the Treatment Strategy

Mary Caffrey Laura Joszt, MA
The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.
Breyanzi packaging | Image credit: BMS
May 30th 2024

FDA Approves Liso-Cel to Treat R/R Mantle Cell Lymphoma

Mary Caffrey
Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy.
Rajni Natesan, MD, MBA | Image credit: Clarified Precision Medicine
May 24th 2024

Bringing the Human Factor to the “Last Mile” of AI-Assisted Clinical Decisions

Mary Caffrey
Doctor with health care icons and FDA | Image credit: wladimir1804 - stock.adobe.com
May 17th 2024

Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC

Laura Joszt, MA
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
Lung cancer diagnosis concept | Image Credit: VitaliiVodolazskyi-stock.adobe.com
May 16th 2024

Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial

Maggie L. Shaw
This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
U.S. Food and Drug Administration FDA approved | Calin - stock.adobe.com
May 16th 2024

FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma

Pearl Steinzor
FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.
Keytruda packaging | Image credit: Merck
May 9th 2024

Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer

Mary Caffrey
Pembrolizumab has existing indications in endometrial cancer.
Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Mary Caffrey
Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.
Nature Medicine logo | Image credit: Nature Medicine
May 4th 2024

Study Shows Potential for Using Nivolumab Plus Relatlimab Before Surgery in NSCLC

Mary Caffrey
Authors discuss the merits of using a pair of immunotherapy treatments aimed at separate targets.
Javier Pinilla-Ibarz, MD, PhD | Image credit: Targeted Oncology
April 30th 2024

T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need

Mary Caffrey
"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges.
Anktiva packaging | Image credit: ImmunityBio
April 23rd 2024

Nogapendekin Alfa Inbakicept With BCG Approved for Type of Bladder Cancer

Mary Caffrey
The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer.
Clear cell carcinoma | Image credit: Sunnybrook Health Sciences Center
April 22nd 2024

Young Woman With Rare Cervical Cancer Achieves Remission After Nivolumab Before Chemoradiotherapy

Mary Caffrey
A tumor board looked to studies in ovarian cancer for guidance on use of immunotherapy in a rare case of clear cell carcinoma of the cervix.
what we're reading logo
April 19th 2024

What We’re Reading: Health Care Antitrust Portal; CAR T Label Updates; Weight-Loss Shots and Fertility

AJMC Staff
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Columvi packaging | Image: Genentech
April 15th 2024

STARGLO: Glofitamab Plus Chemo Meets Primary OS End Point in R/R DLBCL in Phase 3 Study

AJMC Staff
Results show the bispecific antibody is effective in an earlier line of treatment.
AJMC EBO logo | Image credit : AJMC
April 15th 2024

Health Care Practitioners Push for Legislative Solution to Prevent Chemotherapy Shortage “Groundhog Day”

Ryan Flinn
Fred Locke, MD | Image credit: Moffitt Cancer Center
April 3rd 2024

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL?

Mary Caffrey
The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.
FCS logo | Image credit: FCS
April 2nd 2024

Florida Cancer Specialists & Research Institute Forms Analytics Subsidiary

AJMC Staff
Opdivo and Yervoy | Image credit: Bristol Myers Squibb
March 30th 2024

Review: Neoadjuvant Dual ICIs Offer Better Response Than Anti-PD1 Monotherapy in High-Risk Resectable Melanoma

Mary Caffrey
An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.
Man receiving infusion | Image credit: National Cancer Institute
March 28th 2024

Immunotherapy Before Noon Linked to Improved Survival in mRCC

Mary Caffrey
Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.
Princess Catherine, Duchess of Wales | Image credit: Wikipedia
March 23rd 2024

Preventative Chemotherapy? Not Quite, but Studies Are Underway in Immunoprevention

Mary Caffrey
The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.
Keytruda packaging | Image credit: Merck
March 21st 2024

Pembrolizumab Plus Olaparib Falls Short in Phase 3 Study When Used First Line in Metastatic, Nonsquamous NSCLC

Mary Caffrey
This is the second time the combination has failed to meet end points in a trial in non–small cell lung cancer (NSCLC).
FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors
March 15th 2024

FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors

Mary Caffrey
The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.
Registry Data Inconclusive on Risk of Secondary Primary Malignancy After CAR T, Authors Say
March 14th 2024

Registry Data Inconclusive on Risk of Secondary Primary Malignancy After CAR T, Authors Say

Mary Caffrey
Results come amid the FDA's review of chimeric antigen receptor (CAR) T-cell therapy.
researcher in lab | Image credit: StockPhotoPro - stock.adobe.com
March 8th 2024

Real-World Study Confirms Nivolumab Plus Ipilimumab Safety in Advanced NSCLC

Skylar Jeremias
A real-world study confirmed that the rate of adverse events associated with first-line nivolumab plus iplimumab therapy was in line with the safety profiles of other immuno-oncology and chemotherapy combination regimens.
Clinician touching a graphic saying FDA Approved | image credit: wladimir1804 - stock.adobe.com
March 7th 2024

Frontline Nivolumab Plus Chemotherapy Approved for Unresectable or Metastatic Urothelial Carcinoma

Laura Joszt, MA
The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population.
Top 5 Immuno-Oncology Articles of 2023
December 26th 2023

Top 5 Most-Read Immuno-Oncology Articles of 2023

Rose McNulty
12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo